Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.92 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.92 |
| ▸ | MMP9 | P14780 | 11/20 | 0.79 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | MMP1 | P03956 | 1/20 | 0.70 |
| ▸ | MMP3 | P08254 | 1/20 | 0.70 |
| ▸ | MMP7 | P09237 | 1/20 | 0.70 |
| ▸ | MMP13 | P45452 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009406 | 1.00 | MMP2 (0.92) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3009401 | 1.00 | MMP2 (0.92) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL29527231 | 0.94 | MMP2 (0.82) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3890915 | 0.90 | MMP2 (0.76) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3890918 | 0.90 | MMP2 (0.76) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL697592 | 0.90 | MMP2 (0.85) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL697591 | 0.90 | MMP2 (0.85) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL4188026 | 0.90 | MMP2 (0.85) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL6418857 | 0.89 | MMP2 (0.74) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL6418848 | 0.89 | MMP2 (0.74) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197749-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB | 2010-08-05 | — | — | US | disclosed |
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| EP-2013184-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1979332-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007129019-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| EP-1377542-B1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | AMBRILIA BIOPHARMA INC (CA) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007083089-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | WO | disclosed |
| EP-1803706-A1 | HIV protease inhibitors based on amino acid derivatives | Ambrilia Biopharma Inc. (CA) | 2007-07-04 | — | — | EP | disclosed |
| US-6677367-B2 | LYSINE DERIVATIVE WITH 2-AMINOSULFONYLTHIOPHENE SUBSTITUENT; ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) VIRICIDES | PHARMACOR INC. (CA) | 2004-01-13 | — | — | US | disclosed |
| EP-1377542-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | Pharmacor Inc. (CA) | 2004-01-07 | — | — | EP | disclosed |
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-07-31 | — | — | US | disclosed |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-06-26 | — | — | US | disclosed |
| US-6506786-B2 | Such as N-isobutyl-N-(4-methylbenzene-sulfonyl)-N-(N-(4-methylbenzenesulfonyl)-L -phenylalanyl)-L-lysine | PHARMACOR INC. (CA) | 2003-01-14 | — | — | US | disclosed |
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2002-10-17 | — | — | US | disclosed |
| WO-2002064551-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | PHARMACOR INC. (CA) | 2002-08-22 | — | — | WO | disclosed |
| US-5792869-A | REACTING PIPERAZINE DERIVATIVE WITH SULFONAMIDE DERIVATIVE OF OPTICALLY ACTIVE AMINO ACID, PRECIPITATING LESS SOLUBLE SALT, SEPARATING, DECOMPOSING TO DESIRED DIASTEREOMER | YAMAKAWA CHEMICAL INDUSTRY CO., LTD (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0710652-B1 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL IND (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5650428-A | THROMBOXANE A2 ANTAGONISM | NKK CORPORATION (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0710652-A2 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| CN-1111453-A | Aryl sulfonamide derivatives and pharmaceutical compositions containing the same | NIPPON KOKAN KK (JP) | 1995-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | MMP2 845/4885ADAMTS5 3651/4885MMP9 732/4885 |
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | MMP2 845/4885ADAMTS5 3651/4885MMP9 732/4885 |
| US-20100197749-A1 | CHEMICAL COMPOUNDS | EDF1, ECE1, EDNRA | MMP2 2309/4885ADAMTS5 582/4885MMP9 3346/4885 |
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ADGRE5, ADGRF1, SELPLG | MMP2 3625/4885ADAMTS5 891/4885MMP9 3153/4885 |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | MMP2 845/4885ADAMTS5 3651/4885MMP9 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.